Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

23.59 +0.17 (+0.73%)
Streaming Delayed Price Updated: 9:50 AM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GH Research PLC - Ordinary Shares

< Previous 1 2 Next >
News headline image
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
From GH Research PLC
Via GlobeNewswire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
GH Research Announces Publication of Phase 2a Postpartum Depression Results
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Pricing of $117.5 Million Underwritten Offering
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research to Announce IND Status for GH001
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Global Pivotal Program Plans and Further Development Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Pricing of $150 Million Public Offering
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Proposed Public Offering
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
From GH Research PLC
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.